Fluvoxamine treatment of major depression associated with multiple sclerosis
- PMID: 15377746
- DOI: 10.1176/jnp.16.3.364
Fluvoxamine treatment of major depression associated with multiple sclerosis
Abstract
Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
